IMMUNOLOGY2026™ Conference Recordings For Attendees-Interdisciplinary design of NK-based immunotherapies

Video Transcription

Video Summary

The speaker presented an interdisciplinary program to develop NK-cell-based immunotherapies. NK cells can attack tumors that escape T-cell surveillance, making them useful partners to existing cancer treatments. The work focused on four areas: new antibody targets, NK cell engagers, engineered NK cells, and immunocytokines. Key targets included the PVR family members PVRIG, CD96, TIGIT, and CD155, with several antibodies already in clinical development. The team also studied CD49A-positive NK cells, showing they may act as a checkpoint and that blocking CD49A can slow tumor growth and improve survival.  <br /><br />For NK cell engagers, they found strong activity when enough NK cells are present, and designed a CD16-IL-2-CD19 engager that activated NK cells and depleted B cells safely in monkeys. They also engineered NK cells by modifying intracellular regulators like TIPPIT2 and FBXO38 to improve anti-tumor activity. Finally, they developed logic-gated NK systems and PD-1/IL-2 fusion proteins to boost efficacy while reducing toxicity.

Meta Tag

Date April 18, 2026 10:39 AM - 10:57 AM

Room 153C

Session A New Era in Interdisciplinary Immunotherapy, Sponsored by the Chinese Soc. for Immunol. (CSI)

Speaker Haoyu Sun

Track Translational and Interventional Immunology (TI)

Year 2026

Keywords

NK-cell immunotherapy

PVR family targets

CD49A checkpoint

NK cell engagers

engineered NK cells

April 18, 2026 10:39 AM - 10:57 AM

153C

A New Era in Interdisciplinary Immunotherapy, Sponsored by the Chinese Soc. for Immunol. (CSI)

Haoyu Sun

Translational and Interventional Immunology (TI)

2026